Treatment of attention-deficit/hyperactivity disorder
View Patent ↗3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.
1. A method of treating attention-deficit/hyperactivity disorder in a subject in need thereof, comprising administering to a human patient in need of treatment for attention-deficit/hyperactivity disorder an amount of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof that is 4 milligrams administered twice in a twenty-four hour period and the amount of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof administered provides a plasma area under the curve (AUC) ratio that reduces symptom severity while minimizing adverse drug effect.
2. The method of claim 1 , wherein the administration of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof provides a mean Cmax that is from about 5-15 ng/mL.
3. The method of claim 1 , wherein the administration of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof provides an AUC 12 for 4 mg BID ranged that is from about 72-114 ng.hr/mL.